These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

634 related articles for article (PubMed ID: 33524462)

  • 21. Absence of relevant QT interval prolongation in not critically ill COVID-19 patients.
    Jiménez-Jáimez J; Macías-Ruiz R; Bermúdez-Jiménez F; Rubini-Costa R; Ramírez-Taboada J; Flores PIG; Gallo-Padilla L; García JDM; García CM; Suárez SM; Molina CF; López MÁ; Tercedor L
    Sci Rep; 2020 Dec; 10(1):21417. PubMed ID: 33293554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin.
    Chorin E; Wadhwani L; Magnani S; Dai M; Shulman E; Nadeau-Routhier C; Knotts R; Bar-Cohen R; Kogan E; Barbhaiya C; Aizer A; Holmes D; Bernstein S; Spinelli M; Park DS; Stefano C; Chinitz LA; Jankelson L
    Heart Rhythm; 2020 Sep; 17(9):1425-1433. PubMed ID: 32407884
    [TBL] [Abstract][Full Text] [Related]  

  • 23. QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis.
    Diaz-Arocutipa C; Brañez-Condorena A; Hernandez AV
    Pharmacoepidemiol Drug Saf; 2021 Jun; 30(6):694-706. PubMed ID: 33772933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. QT Interval Prolongation Under Hydroxychloroquine/Azithromycin Association for Inpatients With SARS-CoV-2 Lower Respiratory Tract Infection.
    Bun SS; Taghji P; Courjon J; Squara F; Scarlatti D; Theodore G; Baudouy D; Sartre B; Labbaoui M; Dellamonica J; Doyen D; Marquette CH; Levraut J; Esnault V; Bun SS; Ferrari E
    Clin Pharmacol Ther; 2020 Nov; 108(5):1090-1097. PubMed ID: 32588427
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing QT interval in COVID-19 patients:safety of hydroxychloroquine-azithromycin combination regimen.
    Bernardini A; Ciconte G; Negro G; Rondine R; Mecarocci V; Viva T; Santini F; de Innocentiis C; Giannelli L; Witkowska E; Locati ET; Castelvecchio S; Marrocco-Trischitta MM; Vicedomini G; Menicanti L; Pappone C
    Int J Cardiol; 2021 Feb; 324():242-248. PubMed ID: 32956782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ventricular repolarization indexes in patients treated with hydroxychloroquine - azithromycin combination for COVID-19.
    Gunay S; Caliskan S; Sigirli D; Sahin E
    Bratisl Lek Listy; 2020; 121(11):817-821. PubMed ID: 33164544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Validating and implementing cardiac telemetry for continuous QTc monitoring: A novel approach to increase healthcare personnel safety during the COVID-19 pandemic.
    Kassis N; Tanaka-Esposito C; Chung R; Kalra A; Shao M; Kumar A; Alzubi J; Chung MK; Khot UN
    J Electrocardiol; 2021; 67():1-6. PubMed ID: 33975077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19.
    Echarte-Morales J; Minguito-Carazo C; Del Castillo-García S; Borrego-Rodríguez J; Rodríguez-Santamarta M; Sánchez-Muñoz E; Bergel-García R; González-Maniega C; Prieto-González S; Menéndez-Suarez P; Tundidor-Sanz E; Benito-González T; Fernández-Vázquez F
    J Electrocardiol; 2021; 64():30-35. PubMed ID: 33307378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hydroxychloroquine and Azithromycin Combination in the Management of COVID-19 Infection: Safety and Effectiveness Challenges.
    Abou Warda AE; Tammam M; El-Gazar RA; Sarhan RM; Gaber S
    Curr Drug Saf; 2022; 17(2):143-151. PubMed ID: 34315385
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.
    Saleh M; Gabriels J; Chang D; Soo Kim B; Mansoor A; Mahmood E; Makker P; Ismail H; Goldner B; Willner J; Beldner S; Mitra R; John R; Chinitz J; Skipitaris N; Mountantonakis S; Epstein LM
    Circ Arrhythm Electrophysiol; 2020 Jun; 13(6):e008662. PubMed ID: 32347743
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of hydroxychloroquine-azithromycin combination on Tpeak-to-end and Tpeak-to-end/QT ratio during a short treatment course.
    Bakhshaliyev N; Özdemir R
    Ann Noninvasive Electrocardiol; 2021 Jul; 26(4):e12846. PubMed ID: 33956361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings.
    Gasperetti A; Biffi M; Duru F; Schiavone M; Ziacchi M; Mitacchione G; Lavalle C; Saguner A; Lanfranchi A; Casalini G; Tocci M; Fabbricatore D; Salghetti F; Mariani MV; Busana M; Bellia A; Cogliati CB; Viale P; Antinori S; Galli M; Galiè N; Tondo C; Forleo GB
    Europace; 2020 Dec; 22(12):1855-1863. PubMed ID: 32971536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. QTc interval prolongation associated with inpatient azithromycin therapy for pneumonia.
    Dela Cruz M; Ershad M; Mostafa A
    J Osteopath Med; 2021 Jan; 121(1):5-9. PubMed ID: 33044496
    [TBL] [Abstract][Full Text] [Related]  

  • 34. "Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers.
    Gérard A; Romani S; Fresse A; Viard D; Parassol N; Granvuillemin A; Chouchana L; Rocher F; Drici MD;
    Therapie; 2020; 75(4):371-379. PubMed ID: 32418730
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The evaluation of the short-term and long-term hydroxychloroquine therapy on ECG parameters.
    Uyar S; Kök M; Ayan A; Coşkuner MA; Köker G; Koca N
    Medicine (Baltimore); 2024 Aug; 103(32):e39039. PubMed ID: 39121326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medication safety in a pandemic: A multicentre point prevalence study of QTc monitoring of hydroxychloroquine for COVID-19.
    Smoke SM; Leach H; Leonida N; Raja K; Shah M; Patel V; Patel G; Daniel NM; Gerges J; Patel A
    J Clin Pharm Ther; 2021 Oct; 46(5):1308-1311. PubMed ID: 33959987
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Manual vs. automatic assessment of the QT-interval and corrected QT.
    Neumann B; Vink AS; Hermans BJM; Lieve KVV; Cömert D; Beckmann BM; Clur SB; Blom NA; Delhaas T; Wilde AAM; Kääb S; Postema PG; Sinner MF
    Europace; 2023 Aug; 25(9):. PubMed ID: 37470430
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of hydroxychloroquine and azithromycin on the corrected qt interval in patients with the novel Coronavirus disease 2019.
    Murat B; Akgun H; Akarsu M; Ozmen A; Murat S
    Rev Assoc Med Bras (1992); 2021 Jul; 67(7):979-984. PubMed ID: 34817510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular Safety of Azithromycin in Patients Hospitalized With COVID-19: A Prespecified Pooled Analysis of the COALITION I and COALITION II Randomized Clinical Trials.
    Furtado RHM; Barros E Silva PGM; Fonseca HAR; Serpa-Neto A; Correa TD; Guimarães HP; Pereira AJ; Olivato GB; Zampieri FG; Lisboa T; Junqueira DLM; Lapa MG; Monfardini F; Damiani LP; Echenique LS; Gebara OE; Hoffman Filho CR; Polanczyk CA; Rohde LE; Amazonas R; Machado FR; Avezum A; Azevedo LCP; Veiga VC; Rosa RG; Lopes RD; Cavalcanti AB; Berwanger O;
    Am J Cardiol; 2024 Mar; 214():18-24. PubMed ID: 38104755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of triple antimicrobial therapy on electrocardiography parameters in patients with mild-to-moderate coronavirus disease 2019.
    Uğurlu Ilgın B; Akbulut Koyuncu İM; Kızıltunç E
    Anatol J Cardiol; 2021 Mar; 25(3):184-190. PubMed ID: 33690133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.